相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Epigenetic downregulation of TET3 reduces genome-wide 5hmC levels and promotes glioblastoma tumorigenesis
Antonella Carella et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Specific glioblastoma multiforme prognostic-subtype distinctions based on DNA methylation patterns
Huihui Ma et al.
CANCER GENE THERAPY (2020)
A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity
Fadi Jacob et al.
CELL (2020)
Molecular subtypes and precision treatment of triple-negative breast cancer
Shen Zhao et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma
Ae Kyung Park et al.
NEURO-ONCOLOGY (2019)
Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis
Y. Li et al.
EUROPEAN UROLOGY SUPPLEMENTS (2019)
Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors
Niklas Schaefer et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma
Xuejiao Liu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Gliosarcoma: distinct molecular pathways and genomic alterations identified by DNA copy number/SNP microarray analysis
Lindsey Lowder et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling
Youzhou Sang et al.
NEURO-ONCOLOGY (2019)
Relevance of a TCGA-derived Glioblastoma Subtype Gene-Classifier among Patient Populations
Wan-Yee Teo et al.
SCIENTIFIC REPORTS (2019)
Transcriptome profiling-based identification of prognostic subtypes and multi-omics signatures of glioblastoma
Junseong Park et al.
SCIENTIFIC REPORTS (2019)
Comprehensive genetic alteration profiling in primary and recurrent glioblastoma
Beth K. Neilsen et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha
Inan Olmez et al.
NEURO-ONCOLOGY (2018)
Distinct chromatin signatures of DNA hypomethylation in aging and cancer
Raul F. Perez et al.
AGING CELL (2018)
A novel prognostic six-CpG signature in glioblastomas
An-An Yin et al.
CNS NEUROSCIENCE & THERAPEUTICS (2018)
Analysis of DNA methylation in cancer: location revisited (vol 15, pg 459, 2018)
Alexander Koch et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications
Zhenghao Li et al.
ONCOGENE (2018)
Current Challenges and Opportunities in Treating Glioblastoma
Andrea Shergalis et al.
PHARMACOLOGICAL REVIEWS (2018)
Comparison of glioblastoma (GBM) molecular classification methods
Eunjee Lee et al.
SEMINARS IN CANCER BIOLOGY (2018)
DNA methylation as an epigenetic regulator of gallbladder cancer: An overview
Jibran Sualeh Muhammad et al.
INTERNATIONAL JOURNAL OF SURGERY (2018)
DNMT1 regulates expression of MHC class I in post-mitotic neurons
Julie Ry Gustafsson et al.
MOLECULAR BRAIN (2018)
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide An Analysis From the NRG Oncology/RTOG 0424 Trial
Erica H. Bell et al.
JAMA ONCOLOGY (2018)
Epigenetic biomarkers of promoter DNA methylation in the new era of cancer treatment
Keishi Yamashita et al.
CANCER SCIENCE (2018)
Promoter methylation of Wrap53 alpha, an antisense transcript of p53, is associated with the poor prognosis of patients with non-small cell lung cancer
Dong Sun Kim et al.
ONCOLOGY LETTERS (2018)
Epigenetic Targeting of Glioblastoma
Massimo Romani et al.
FRONTIERS IN ONCOLOGY (2018)
Immunogenetics of glioblastoma: the future of personalized patient management
Malak Abedalthagafi et al.
NPJ PRECISION ONCOLOGY (2018)
Combination therapy to checkmate Glioblastoma: clinical challenges and advances
Debarati Ghosh et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2018)
MGMT Gene Promoter Methylation Status - Assessment of Two Pyrosequencing Kits and Three Methylation-specific PCR Methods for their Predictive Capacity in Glioblastomas
Lene E. Johannessen et al.
CANCER GENOMICS & PROTEOMICS (2018)
Glioblastoma under Siege: An Overview of Current Therapeutic Strategies
Mayra Paolillo et al.
BRAIN SCIENCES (2018)
Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives
Wojciech Szopa et al.
BIOMED RESEARCH INTERNATIONAL (2017)
DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas
Yashna Paul et al.
CLINICAL EPIGENETICS (2017)
Angiogenic Gene Signature Derived from Subtype Specific Cell Models Segregate Proneural and Mesenchymal Glioblastoma
Aman Sharma et al.
FRONTIERS IN ONCOLOGY (2017)
Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice
Rimas V. Lukas et al.
NEURO-ONCOLOGY PRACTICE (2017)
Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors
Joerg Felsberg et al.
CLINICAL CANCER RESEARCH (2017)
Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment
Qianghu Wang et al.
CANCER CELL (2017)
Epithelioid Glioblastomas and Anaplastic Epithelioid Pleomorphic Xanthoastrocytomas-Same Entity or First Cousins?
Sanda Alexandrescu et al.
BRAIN PATHOLOGY (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma
Michele Ceccarelli et al.
CELL (2016)
Drug repurposing for glioblastoma based on molecular subtypes
Yang Chen et al.
JOURNAL OF BIOMEDICAL INFORMATICS (2016)
TERT mutation in glioma: Frequency, prognosis and risk
Yang Yuan et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2016)
Clonal evolution of glioblastoma under therapy
Jiguang Wang et al.
NATURE GENETICS (2016)
Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas
Pei Yang et al.
NEURO-ONCOLOGY (2016)
A comprehensive profile of recurrent glioblastoma
B. Campos et al.
ONCOGENE (2016)
Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model
Matheus H. W. Crommentuijn et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
Johanna Mondesir et al.
JOURNAL OF BLOOD MEDICINE (2016)
Prognostic value of epidermal growth factor receptor amplification and EGFRvIII in glioblastoma: meta-analysis
J. -R. Chen et al.
ACTA NEUROLOGICA SCANDINAVICA (2015)
Spatiotemporal Evolution of the Primary Glioblastoma Genome
Jinkuk Kim et al.
CANCER CELL (2015)
Colorectal Cancer Heterogeneity and Targeted Therapy: A Case for Molecular Disease Subtypes
Janneke F. Linnekamp et al.
CANCER RESEARCH (2015)
New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma
Lilia Dimitrov et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2015)
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial
Thomas Sandmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells
Ayal Hendel et al.
NATURE BIOTECHNOLOGY (2015)
Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis
Sabine Spiegl-Kreinecker et al.
NEURO-ONCOLOGY (2015)
Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas
Martin J. van den Bent et al.
NEURO-ONCOLOGY (2015)
Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes
Marc C. Chamberlain et al.
NEUROLOGY (2015)
TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma
Mohamed Ali Mosrati et al.
ONCOTARGET (2015)
Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics
Rui Li et al.
ONCOTARGET (2015)
Treatment Considerations for MGMT-Unmethylated Glioblastoma
Jennie W. Taylor et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2015)
International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading
David N. Louis et al.
BRAIN PATHOLOGY (2014)
A vaccine targeting mutant IDH1 induces antitumour immunity
Theresa Schumacher et al.
NATURE (2014)
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection
Jason Beiko et al.
NEURO-ONCOLOGY (2014)
Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastoma
A. Broniscer et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2014)
IDH1/IDH2 but Not TP53 Mutations Predict Prognosis in Bulgarian Glioblastoma Patients
Gergana Stancheva et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolornide in newly diagnosed, MGMT-non-methylated glioblastoma patients
Ulrich Herrlinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Epithelioid GBMs Show a High Percentage of BRAF V600E Mutation
Bette Kay Kleinschmidt-DeMasters et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
The Definition of Primary and Secondary Glioblastoma
Hiroko Ohgaki et al.
CLINICAL CANCER RESEARCH (2013)
Molecular subtypes of glioma identified by genome-wide methylation profiling
Nanne K. Kloosterhof et al.
GENES CHROMOSOMES & CANCER (2013)
Changes in Transcriptional Factor Binding Capacity Resulting from Promoter Region Methylation Induce Aberrantly High GDNF Expression in Human Glioma
Zheng-Quan Yu et al.
MOLECULAR NEUROBIOLOGY (2013)
Standards of care for treatment of recurrent glioblastoma-are we there yet?
Michael Weller et al.
NEURO-ONCOLOGY (2013)
An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
Dan Rohle et al.
SCIENCE (2013)
MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma
Daina Skiriute et al.
BMC CANCER (2012)
IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma
Qi SongTao et al.
CANCER SCIENCE (2012)
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials
Thierry Gorlia et al.
EUROPEAN JOURNAL OF CANCER (2012)
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Chao Lu et al.
NATURE (2012)
G-Cimp Status Prediction Of Glioblastoma Samples Using mRNA Expression Data
Mehmet Baysan et al.
PLOS ONE (2012)
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response
Nicholas J. Szerlip et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma
Brock C. Christensen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Preclinical Differences of Intravascular AAV9 Delivery to Neurons and Glia: A Comparative Study of Adult Mice and Nonhuman Primates
Steven J. Gray et al.
MOLECULAR THERAPY (2011)
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Eric A. Collisson et al.
NATURE MEDICINE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Epithelioid Versus Rhabdoid Glioblastomas Are Distinguished by Monosomy 22 and Immunohistochemical Expression of INI-1 but not Claudin 6
Bette Kay Kleinschmidt-DeMasters et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
Tumor heterogeneity: Causes and consequences
Andriy Marusyk et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2010)
DNA methylation in glioblastoma: impact on gene expression and clinical outcome
Amandine Etcheverry et al.
BMC GENOMICS (2010)
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Houtan Noushmehr et al.
CANCER CELL (2010)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
CpG Island Hypermethylation in Human Astrocytomas
Xiwei Wu et al.
CANCER RESEARCH (2010)
Age-dependent prognostic effects of EGFR/p53 alterations in glioblastoma: study on a prospective cohort of 140 uniformly treated adult patients
M. R. Srividya et al.
JOURNAL OF CLINICAL PATHOLOGY (2010)
A multigene predictor of outcome in glioblastoma
Howard Colman et al.
NEURO-ONCOLOGY (2010)
Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance
Kimmo J. Hatanpaa et al.
NEOPLASIA (2010)
IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas
Takuya Watanabe et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
Sumihito Nobusawa et al.
CLINICAL CANCER RESEARCH (2009)
Epigenetic markers as promising prognosticators for bladder cancer
Young Kyoon Kim et al.
INTERNATIONAL JOURNAL OF UROLOGY (2009)
The EGFRvIII variant in glioblastoma multiforme
Hui K. Gan et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2009)
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas
Koichi Ichimura et al.
NEURO-ONCOLOGY (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations
Cameron Brennan et al.
PLOS ONE (2009)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
PTEN signaling in brain: neuropathology and tumorigenesis
R. Endersby et al.
ONCOGENE (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter
Marta M. Alonso et al.
CANCER RESEARCH (2007)
Genetic pathways to primary and secondary glioblastoma
Hiroko Ohgaki et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Correlation among pathology, genotype, and patient outcomes in glioblastoma
Taku Homma et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2006)
The molecular portraits of breast tumors are conserved across microarray platforms
Zhiyuan Hu et al.
BMC GENOMICS (2006)
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
HS Phillips et al.
CANCER CELL (2006)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients
AB Heimberger et al.
CLINICAL CANCER RESEARCH (2005)
Summaries of affymetrix GeneChip probe level data
RA Irizarry et al.
NUCLEIC ACIDS RESEARCH (2003)
DNA methylation markers in patients with gastrointestinal cancers
C Lofton-Day et al.
DIGESTIVE DISEASES (2003)
Comparison of discrimination methods for the classification of tumors using gene expression data
S Dudoit et al.
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION (2002)
分享论文
